Rebif Sales Data
| Rank 50 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Rebif U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 50 ( 9) |
$280,548 | -6.27% | 395 | -12.61% |
| Q3 2013 | 41 (3) |
$299,305 | -8.17% | 452 | -14.07% |
| Q2 2013 | 38 ( 3) |
$325,937 | -1.96% | 526 | -6.41% |
| Q1 2013 | 41 (3) |
$332,452 | 6.61% | 562 | -8.17% |
| Q4 2012 | 38 (4) |
$311,851 | 1.13% | 612 | -3.92% |
| Q3 2012 | 42 (7) |
$308,352 | 8.88% | 637 | 11.36% |
| Q2 2012 | 49 (13) |
$283,208 | 9.73% | 572 | 5.93% |
| Q1 2012 | 62 (1) |
$258,088 | -0.21% | 540 | -9.09% |
| Q4 2011 | 61 (7) |
$258,643 | 0.43% | 594 | -0.34% |
| Q3 2011 | 54 (5) |
$257,535 | 1.48% | 596 | -1.49% |
| Q2 2011 | 59 (2) |
$253,780 | 0.25% | 605 | -0.66% |
| Q1 2011 | 61 | $253,143 | n/a | 609 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
